Skip to main content

Equibles does not estimate personal net worth.

Get an email with a short summary when Beam Therapeutics Inc. publishes a filing, an earnings call transcript or a press release.

Get BEAM alerts

About John Evans

John Evans is recorded as Chief Accounting Officer at Beam Therapeutics Inc. (BEAM) since August 9, 2024, CEO and Board Member at Beam Therapeutics Inc. (BEAM) and Head of Investor Relations at GrowGeneration Corp. (GRWG). The newest filing on record that lists John Evans as CEO and Board Member at Beam Therapeutics Inc. (BEAM) is dated April 17, 2026. The proxy statement of Beam Therapeutics Inc. reports total compensation of $5,818,525 for John Evans in fiscal 2025, including a base salary of $755,000. Disclosed compensation is on record for 7 fiscal years. John Evans has spoken on 3 earnings calls and 4 other investor events across 2 companies, most recently for Beam Therapeutics Inc. on November 17, 2026. Those appearances were for Beam Therapeutics Inc. (BEAM) and GrowGeneration Corp. (GRWG). Beam Therapeutics Inc. is classified in the Biotechnology industry within the Healthcare sector. GrowGeneration Corp. is classified in the Specialty Retail industry within the Consumer Cyclical sector. Other leadership on record at Beam Therapeutics Inc. includes Sravan Emany (CFO), Sravan K. Emany (CFO), Chirfi Guindo (Board Member) and 6 others.

John Evans on recent calls

“I think this is the year when the full potential of this platform that we've been building is now really visible, particularly the fact that it is a platform technology.”
CEO, UBS Global Biopharma Conference ·
“We're moving very quickly now across a broad range of programs, all building off of this very dynamic platform that we've created using base editing, of course, next generation CRISPR 2.0 technology for more precise gene editing. but then building that into a delivery and manufacturing machinery that that is now quite…”
CEO, Citi's 2026 Biopharma Back to School Conference ·
“So Beam is a platform company developing a really novel and innovative technology called base editing. So here we're doing genetic correction of genes at the single-letter level.”
CEO, Wells Fargo 21st Annual Healthcare Conference ·
“So Beam Therapeutics is a next generation gene editing company. We're working on a new form of CRISPR called base editing. And so this allows us to make single letter changes in genes on a permanent basis without needing to make a double strain and break.”
CEO, 2026 RBC Capital Markets Healthcare Conference ·
“At BEAN, our vision is straightforward but ambitious to provide lifelong cures for patients suffering from serious diseases. We believe base editing has the potential to deliver on that vision through one-time, durable genetic medicines with predictable and reproducible outcomes.”
CEO, Beam Therapeutics Inc. Q4 FY2025 Earnings Call ·

Affiliation history

Company network

Leadership on record at Beam Therapeutics Inc.

Leadership on record at GrowGeneration Corp.

Executive compensation

Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.

Fiscal year Company Salary Total
2025 Beam Therapeutics Inc. (BEAM) $755,000 $5,818,525
2024 Beam Therapeutics Inc. (BEAM) $715,750 $6,409,631
2023 Beam Therapeutics Inc. (BEAM) $685,000 $6,280,099
2022 Beam Therapeutics Inc. (BEAM) $650,000 $9,496,745
2021 Beam Therapeutics Inc. (BEAM) $590,105 $13,911,975
2020 Beam Therapeutics Inc. (BEAM) $529,271 $906,768
2019 Beam Therapeutics Inc. (BEAM) $472,500 $2,209,800

Recent activity